Niki Karachaliou, MD
Pangaea Biotech, USP Instituto Universitario Dexeus, Barcelona, Spain
Mrs Niki Karachaliou is a Medical Oncologist and she is a member of the Translational Research Group in Pangaea Biotech SA (Barcelona). She was admitted to the University of Athens - Medical School after National Examination in 1994 and she completed her graduate studies (1994-2002) with the score 9/10 (duration of studies: 6 years); afterwards she did her 2-year rural medical practice (2002-2004). She completed internal medicine residency at the General Hospital of Chalkida in Evoia-Greece (2005-2008), including six months of haematology at the 3rd Dept of University Hematological Department, of Sotiria Hospital in Athens. Thereafter she completed her fellowship in Medical Oncology at the University Hospital of Heraklion- Crete-Greece (2008 – 2011). In 2010 the elaboration of her PhD Thesis entitled: “Prognostic and/or predictive value of ERCC1, BRCA1, ATP7B, TOPOI, TOPOIIA, TOPOIIB, PKM2 and c-MYC genes in patients with small cell lung cancer (SCLC)” was approved by the council of Medical School, University of Crete (22/03/2010) with Prof. V. Georgoulias being Supervisor. She is the author of 24 papers published in international peer reviewed journals. Specific areas of interest in oncology include translational research in lung cancer and phase I and II clinical trials.